

NET SALES AS AT DECEMBER 31, 2016

Longjumeau, January 31, 2017

PCAS (Euronext Paris: PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its consolidated net sales as at December 31, 2016.

The PCAS Group had generated consolidated net sales of €192.0 million as at December 31, 2016, representing growth of +7.2% compared to the same period of the previous financial year (+6.5% at a constant exchange rate).

In millions of Euros	2016	2015	Growth in %	2016 At a constant exchange rate	Growth in %
Net sales at December 31	192.0	179.1	7.2%	190.7	6.5%
<i>Pharmaceutical synthesis</i>	<i>130.0</i>	<i>120.8</i>	<i>7.6%</i>	<i>128.8</i>	<i>6.6%</i>
<i>Fine specialty chemicals</i>	<i>62.0</i>	<i>58.3</i>	<i>6.4%</i>	<i>61.9</i>	<i>6.2%</i>

Vincent Touraille, Chief Executive Officer of PCAS, explains: “*Net sales increased in 2016, both in Pharmaceutical Synthesis and Fine Specialty Chemicals. The Group's Current Operating Income should be slightly higher than in 2015, bearing, as expected, additional expenses incurred by the introduction of a new industrial organization to cope with a sustained increase in activity. Net income is also likely to be up compared to 2015 (restated to reflect the effect of €2.9 million of insurance revenue net of tax)*”.

Pharmaceutical Synthesis (67.7%)

The Pharmaceutical Synthesis business generated €130.0 million, up +7.6% on 2015 (+6.6% at a constant exchange rate), which was especially driven by the Exclusive activity.

Fine Specialty Chemicals (32.3%)

Net sales of Fine Specialty Chemicals amounted to €62.0 million, up 6.4% on 2015 (+6.2% at a constant exchange rate), with growth in both Performance Additives and Advanced Specialty Chemicals.



NEXT FINANCIAL DISCLOSURE:

2016 results, on February 21, 2017

ABOUT PCAS

PCAS specializes in the development and production of complex molecules for life sciences and innovative technologies. With 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups.

To find out more about PCAS, visit: www.pcas.com



PCA
LISTED
EURONEXT

PCAS

Vincent Touraille / Eric Moissenot

PCAS

Tel. : +33 1 69 79 61 32
www.pcas.com

NewCap

Emmanuel Huynh / Louis-Victor Delouvrier

NewCap

Financial communication and Investor Relations

Tel. : +33 1 44 71 98 53
pcas@newcap.eu